权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immune, hormonal, and muscle mitochondrial determinants of recovery in Acute Respiratory Distress Syndrome survivors

急性呼吸窘迫综合征幸存者康复的免疫、激素和肌肉线粒体决定因素

基本信息

批准号：
10659639
负责人：
Matthew R Baldwin
金额：
$ 75.46万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10659639
关键词：
Acute Acute Respiratory Distress Syndrome Acute respiratory failure Adult Affect Age Aging American Amino Acids Anti-Inflammatory Agents Bioenergetics Biological Biological Markers Biopsy Blood Flow Cytometry COVID-19 COVID-19 survivors COVID-19/ARDS Clinic Clinical Cohort Studies Communities Data Dehydroepiandrosterone Sulfate Elderly Enrollment Future GDF15 gene Gene Expression Profiling Goals Growth Factor Health Care Costs Hormonal Hormones Hospitals Immune Impairment Inflammation Insulin Interleukin-6 Intervention Limb structure Lung Messenger RNA Mitochondria Mitochondrial Myopathies Morphology Multi-Ethnic Study of Atherosclerosis Muscle Muscle Mitochondria Muscle Weakness National Heart, Lung, and Blood Institute Nested Case-Control Study Outcome Patients Persons Physical Function Plasma Process Recovery Research Priority Role Serum Skeletal Muscle Source Supplementation Survivors TNFRSF1A gene Testosterone Time Universities University Hospitals Walking Work biobank cohort comorbidity coronavirus disease critical period cytokine disability follow-up high dimensionality hormone deficiency improved inhibitor interest lung injury metabolomics mitochondrial dysfunction monocyte mortality muscle strength novel physically handicapped prospective randomized trial sociodemographics systemic inflammatory response targeted therapy trials targeted treatment therapeutic target vastus lateralis

项目摘要

PROJECT SUMMARY Prior to COVID-19, over 150,000 Americans survived Acute Respiratory Distress Syndrome (ARDS) each year. To date, more than 500,000 Americans have survived COVID-19 ARDS. At least half of ARDS survivors have persistent muscle weakness that results in increased disability, healthcare costs, and mortality. There are no targeted therapies to improve muscle strength and physical recovery in ARDS survivors, because the mechanisms underlying these physical impairments and poor recovery are not well understood. The overall hypothesis of the project is that multi-systemic dysregulation that occurs in acute ARDS, persists after hospital discharge in those with persistent physical impairment, and resolves in those who recover physically. The overall objective of the project is to determine whether persistent inflammation from dysregulated monocytes, anabolic hormone deficiencies, and muscle mitochondrial dysfunction at 3 months after hospital discharge are each treatment targets for physical disability in ARDS survivors. To achieve our objective, we will conduct a nested case-control study of cohorts. We will prospectively enroll 345 ARDS survivors at hospital discharge with 12- month longitudinal follow-up from Johns Hopkins University and Columbia University hospitals. Three months after hospital discharge, we will conduct an in-person nested case-control study of 180 ARDS survivors, with case status defined as not-recovered from new disability. Inflammation, anabolic hormone deficiencies, and muscle mitochondrial dysfunction increase with aging and comorbidity, and older adult ARDS survivors are less likely to recover than those who are younger and healthier. Therefore, to determine biomarker levels and muscle mitochondrial dysfunction that are associated with ARDS, independent of age or comorbidity, we will compare ARDS survivors with carefully matched community-dwelling adults from the National Heart Lung and Blood Institute (NHLBI) Multi-Ethnic Study of Atherosclerosis (MESA) and the Columbia University Merritt Center muscle biobank. Across the cohorts, we have carefully coordinated sociodemographic, clinical, and functional assessments to facilitate careful matching. We will conduct rigorous serum biomarker assessments, targeted plasma metabolomics, high dimensional flow cytometry of blood, and muscle biopsy mitochondrial function and gene expression analyses to accomplish our three Aims: (1) to determine the role of monocyte function in recovery from disability in ARDS survivors; (2) to determine the role of anabolic hormone deficiencies in recovery from disability in ARDS survivors; and (3), to determine how plasma biomarkers of mitochondrial myopathy associate with skeletal muscle mitochondrial dysfunction and recovery from disability in ARDS survivors. The overall goal is to conduct epi-mechanistic studies that will inform future post-ARDS randomized trials of targeted anti-inflammatory therapies, hormone supplementation therapies, and muscle mitochondrial therapies that aim to improve physical function in ARDS survivors, a NHBLI research priority.

项目总结